Cite
HARVARD Citation
He, L. et al. (2021). Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy. Lung cancer. pp. 1-8. [Online].